Marker Debt Equity Ratio from 2010 to 2024
| MRKR Stock | USD 4.09 0.11 2.62% |
Debt Equity Ratio | First Reported 2010-12-31 | Previous Quarter 0.35 | Current Value 0.37 | Quarterly Volatility 0.39489739 |
Check Marker Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marker main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.9 M, Selling General Administrative of 5.6 M or Total Revenue of 3.5 M, as well as many exotic indicators such as Price To Sales Ratio of 13.9, Dividend Yield of 0.0 or PTB Ratio of 3.62. Marker financial statements analysis is a perfect complement when working with Marker Therapeutics Valuation or Volatility modules.
Marker | Debt Equity Ratio |
Latest Marker Therapeutics' Debt Equity Ratio Growth Pattern
Below is the plot of the Debt Equity Ratio of Marker Therapeutics over the last few years. It is Marker Therapeutics' Debt Equity Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Marker Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Debt Equity Ratio | 10 Years Trend |
|
Debt Equity Ratio |
| Timeline |
Marker Debt Equity Ratio Regression Statistics
| Arithmetic Mean | (0.02) | |
| Geometric Mean | 0.07 | |
| Coefficient Of Variation | (2,272) | |
| Mean Deviation | 0.27 | |
| Median | 0 | |
| Standard Deviation | 0.39 | |
| Sample Variance | 0.16 | |
| Range | 1.5322 | |
| R-Value | 0.87 | |
| Mean Square Error | 0.04 | |
| R-Squared | 0.77 | |
| Significance | 0.00002 | |
| Slope | 0.08 | |
| Total Sum of Squares | 2.18 |
Marker Debt Equity Ratio History
About Marker Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Marker Therapeutics income statement, its balance sheet, and the statement of cash flows. Marker Therapeutics investors use historical funamental indicators, such as Marker Therapeutics's Debt Equity Ratio, to determine how well the company is positioned to perform in the future. Although Marker Therapeutics investors may use each financial statement separately, they are all related. The changes in Marker Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Marker Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Marker Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Marker Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Debt Equity Ratio | 0.35 | 0.37 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Marker Therapeutics Correlation against competitors. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Marker Stock analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Marker Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marker Therapeutics. If investors know Marker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marker Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.38) | Revenue Per Share 0.375 | Quarterly Revenue Growth 0.008 | Return On Assets (0.38) | Return On Equity (0.88) |
The market value of Marker Therapeutics is measured differently than its book value, which is the value of Marker that is recorded on the company's balance sheet. Investors also form their own opinion of Marker Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Marker Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marker Therapeutics' market value can be influenced by many factors that don't directly affect Marker Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marker Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marker Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marker Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.